BioAge Labs Posts Q3 2026 Net Loss of $33.5 Million; QUELL-CV Fully Enrolled

BioAge Labs reported Q3 2026 revenue of $0.3M and a net loss of $33.5M, or $0.73 per share. Cash reserves totaled $352.3M, expected to last through 2029. Key milestones include completing enrollment in the QUELL-CV trial and dosing the first participant in QUELL-DME. R&D expenses rose to $30.2M from $18.5M year-over-year.

Original reporting
Published Nov 5, 2026, 9:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 9:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
BioAge Labs Posts Q3 2026 Net Loss of $33.5 Million; QUELL-CV Fully Enrolled — source image
Decision brief

The 30-second read

$BIOABearishLow
01

Why it matters

The loss widens significantly year‑over‑year, indicating short‑term pressure but long‑term potential from pipeline milestones.

02

Market read

Primary micro‑cap earnings disclosure; new financials may drive short‑term price movement.

03

What to watch

Potential upside from upcoming QUELL-CV topline data in Q4 2026 and IND submission by year‑end.

Relevance 7/10Novelty 8/10Timing: after-hours release

Background

Quarterly earnings release for BioAge Labs, a Nasdaq‑listed biotech focused on aging therapeutics.

Company-level read

Ticker impact

$BIOABearishMedium confidence
Context

BioAge Labs reported Q3 2026 results with a net loss of $33.5M and $0.3M revenue, the first disclosure of these figures.

Expected impact

likely pressure as investors price in the widening loss and modest revenue

Evidence & confidence

Quarterly earnings are the first report of the numbers; loss exceeds prior period and revenue is minimal, prompting potential sell‑off.

Market effects

Biotech sector may see modest caution as a micro‑cap reports a larger-than‑expected loss.

Limited to U.S. small‑cap biotech investors.

Minimal global impact.

Counterpoint

The cash runway to 2029 could support future upside if upcoming trial data are positive.

Key entities

  • BioAge Labs Inc.

    Nasdaq‑listed biotech reporting Q3 2026 results.

Related articles

$BIOAMedAI 8/10

Five-year data of continuous Leqembi® treatment show increasing benefit over time

BioArctic's partner Eisai presented five-year data from the Clarity AD study, showing continuous Leqembi treatment in early Alzheimer's disease increased clinical benefits over time. 62% of patients treated early showed cognitive improvement. Leqembi reduced cognitive decline by 2.05 points after five years compared to historic data. Eisai and BioArctic collaborate on Leqembi's development and commercialization.

$BIOAMed

BioAge Labs 3Q 2026: Revenue $298K, EPS ($0.73) — 10-Q Summary

BioAge Labs (BIOA) reported 3Q 2026 revenue of $298K, down 85% YoY, and a net loss of $33.5M, up 66% YoY. The decline was due to a $1.7M adjustment in Novartis collaboration revenue. R&D costs rose 63% to $30.2M, driven by BGE-102 trial and manufacturing expenses. The company completed QUELL-CV enrollment and expects topline data in 4Q 2026.

$BIOAMed

BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates

BioAge Labs, Inc. (BIOA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates First participant dosed in QUELL-DME, a Phase 2 trial of BGE-102, a potential best-in-class oral NLRP3 inhibitor, in diabetic macular edema; topline results anticipated in the seco

$BIOAMed

About $352 million in cash and securities could fund BioAge's operations through 2029

BioAge Labs (NASDAQ: BIOA) reported $352M in cash and securities for operations through 2029. It dosed the first participant in a Phase 2 trial for BGE-102 in diabetic macular edema, with results expected in 2H 2027. The QUELL-CV Phase 2 trial for BGE-102 in obesity completed enrollment, with data due in 4Q 2026. The company aims to file an IND for its APJ agonist program by year-end 2026. BioAge also updated its collaborations with Novartis, Lilly, and Deep Origin.

$BIOAMedAI 8/10

BioAge Labs, Inc. recently announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial evaluating once-daily…

BioAge Labs, Inc. (BIOA) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events BioAge Labs, Inc. (the “ Company ”) recently announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial evaluating once-daily oral BGE-102, an NLRP3 inhibitor, in adults with diabetic macular edema (“ DME ”), an